ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND KI67 IN EPITHELIAL OVARIAN TUMOR
DOI:
https://doi.org/10.22159/ajpcr.2024v17i11.52493Keywords:
Ovarian tumors, histological grade, immunohistochemistry, molecular markerAbstract
Objective: The objective of the study was to evaluate epidermal growth factor receptor (EGFR) and Ki67 expression in epithelial ovarian tumors and assess the existence of any correlation between overexpression of these markers and histological grades.
Methods: This prospective study was conducted in the Department of Pathology in a tertiary care hospital of G.S.V.M. Medical College from 2022 to 2024. The study included 50 patients with histologically confirmed epithelial ovarian tumors, whose post-resection specimens were subjected to immunostaining to determine the degree of expression of EGFR and Ki67 proliferation index. Details were noted pertaining to age, tumor type, and histological grade. Statistical analysis included the Chi-square test, which evaluated associations between age, histological grade, EGFR expression, and Ki67 proliferation index.
Results: Most of the participants were below 60 years of age (80%). Most tumors were benign (72%), with serous cystadenoma being the most common (66%). The association between histological grade and age was statistically significant; with benign tumors being more common in patients aged ≤50 years and malignant tumors more frequent in those aged >50 years (p=0.018). EGFR expression was observed in 18% of the tumors, predominantly malignant ones, showing a significant association with tumor malignancy (p<0.001). In addition, the Ki67 proliferation index was significantly higher in malignant tumors (p<0.001), and its levels were associated with EGFR expression (p=0.026).
Conclusion: The study findings suggest that molecular markers such as EGFR and Ki67 may be useful in predicting tumor behavior and guiding tailored treatment strategies for ovarian cancer patients.
Downloads
References
Clement PB, Young RH. Ovarian surface epithelial-stromal tumors. In: Mills SE, Carter D, Greenson JK, Reuter VE, Stoler MH, editors. Sternberg’s Diagnostic Surgical Pathology. 5th ed., Vol. 2. USA: Lippincott Williams and Wilkins; 2012. p. 2278.
Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451-60.
Arora T, Mullangi S, Vadakekut ES, Lekkala MR. Epithelial ovarian cancer. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567760 [Last accessed on 2024 May 06].
Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430-41.
Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 2008;27(3):380-9.
Glaysher S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C, et al. Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer. 2013;109(7):1786-94.
Mazidimoradi A, Momenimovahed Z, Allahqoli L, Tiznobaik A, Hajinasab N, Salehiniya H, et al. The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer. Health Sci Rep. 2022;5(6):e936.
Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and prognostic significance of Ki-67 immunohistochemical expression in surface epithelial ovarian carcinoma. J Clin Diagn Res. 2017;11(2):EC08-12.
Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, et al. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: Evaluation of patient cohort and literature review. Genes Cancer. 2017;8(5-6):589-99.
Henzen‐Logmans SC, Fieret EJ, Berns EM, van der Burg ME, Klijn JG, Foekens JA. Ki‐67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal‐growth‐factor receptor and cathepsin D. Int J Cancer. 1994;57(4):468-72.
Wang K, Li D, Sun L. High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. Onco Targets Ther. 2016;9:377-86.
Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers (Basel). 2021;13(11):2748.
Farrag MS, Emarah Z, Elrefaie W, Farrag NS, Hafez MT, Abdelwahab K. EGFR and HER2 expression in primary ovarian high-grade serous carcinoma and their prognostic value. Res Oncol. 2021;17(1):9-16.
Begum S, Begum F, Gani N, Rahman F, Jahan FI. Relationship of age and different histological types of ovarian tumors. Bangladesh J Obstet Gynaecol. 2017;32(2):99-105.
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005;11(24):8637-43.
Chen M, Yao S, Cao Q, Xia M, Liu J, He M. The prognostic value of Ki67 in ovarian high-grade serous carcinoma: An 11-year cohort study of Chinese patients. Oncotarget. 2016;8(64):107877-85.
Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52.
Qiu D, Cai W, Zhang Z, Li H, Zhou D. High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: Evidence from a meta-analysis. Arch Gynecol Obstet. 2019;299: 1415-27.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Ankita Pathak, Mahendra Singh, Neelima Verma
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
